Important Update: Novartis Acquisition of Regulus Therapeutics
Written on . Posted in News and Events.
Novartis has completed its acquisition of Regulus Therapeutics, the biotechnology company developing farabursen, an investigational therapy designed to target microRNA-17 with the aim of slowing cyst growth and preserving kidney function. The transaction has a potential value of up to USD 1.7 billion, reflecting increased commitment to advancing research and development in ADPKD - an area of considerable unmet medical need.
Early clinical studies of farabursen have demonstrated encouraging safety and efficacy outcomes. Further clinical evaluation will now proceed under Novartis's leadership.
PKD International regards this development as a positive indication of continued investment in innovative therapeutic approaches for ADPKD. The organization will monitor progress closely and provide updates as additional data and regulatory milestones become available.
We remain committed to supporting research, fostering collaboration across stakeholders, and advocating for improved care and outcomes for all those living with ADPKD.